MiSight 1 day is the first one day lens developed for myopia management. Its ActivControl technology ensures consistent myopic defocus across all prescriptions, pupil sizes, and variations in lens centration.
Recognising that all myopia management treatments must be supported by strong evidence, in 2012 CooperVision initiated an international 10 year trial involving 144 children. The first three years were conducted as a randomised, double blind study and produced a 59 per cent slowing in myopia progression with a 52 per cent reduction in axial elongation, which compares favourably with other treatments.1
Recently released four year data shows a continuation of the treatment effect and a significant slowing in progression of children moved from the control group into MiSight 1 day.2
- Chamberlain P, Back A, Lazon P, et al. 3 year effectiveness of a dual-focus 1 day soft contact lens for myopia control. Presented at the 40th British Contact Lens Association Clinical Conference and Exhibition, 10 June 2017; Liverpool, United Kingdom.
- Data on file, CooperVision 2018.